Subjects and lessons to explore.

Law

Cell Biology · Cell Cycle Cell Death

Extrinsic (Death Receptor) Apoptosis Pathway

6 min read
Report an error
Want it in plain words first? Jump to Eli explains — the same idea, no jargon.
On this page 6 sections
  1. In 30 seconds
  2. Why this matters
  3. The college version
  4. Eli explains
  5. Key takeaway
  6. Study tools

In 30 seconds

The extrinsic apoptosis pathway is triggered from outside the cell when death ligands bind to cell-surface death receptors of the tumor necrosis factor (TNF) receptor superfamily. The best-studied are Fas (CD95) binding Fas ligand (FasL) and TRAIL receptors (DR4/DR5) binding TRAIL. Ligand binding clusters the receptors, which recruit the adaptor FADD, which recruits procaspase-8. This assembly — the death-inducing signaling complex (DISC) — brings procaspase-8 molecules into close proximity, activating them by dimerization. Active caspase-8 then either directly activates executioner caspases (Type I cells) or cleaves the BH3-only protein Bid to engage the mitochondrial pathway for amplification (Type II cells).

Why this matters

The extrinsic pathway is how the immune system eliminates infected, damaged, or cancerous cells: cytotoxic T lymphocytes and natural killer cells deliver FasL and TRAIL to kill targets, and this is central to immune surveillance and self-tolerance. Its failure causes autoimmunity and lymphoproliferative disease (e.g., autoimmune lymphoproliferative syndrome, ALPS, from Fas/FasL mutations). Therapeutically, TRAIL-receptor agonists and engineered CAR-T cells exploit the pathway to kill tumors selectively. The pathway also mediates the tumor necrosis activity of TNF-α, though TNFR1 more often signals inflammation/survival via NF-κB — a useful example of receptor context determining life vs. death.

The college version

Core Concept

The extrinsic apoptosis pathway is triggered from outside the cell when death ligands bind to cell-surface death receptors of the tumor necrosis factor (TNF) receptor superfamily. The best-studied are Fas (CD95) binding Fas ligand (FasL) and TRAIL receptors (DR4/DR5) binding TRAIL. Ligand binding clusters the receptors, which recruit the adaptor FADD, which recruits procaspase-8. This assembly — the death-inducing signaling complex (DISC) — brings procaspase-8 molecules into close proximity, activating them by dimerization. Active caspase-8 then either directly activates executioner caspases (Type I cells) or cleaves the BH3-only protein Bid to engage the mitochondrial pathway for amplification (Type II cells).

Key Components

  • Death ligands: FasL, TNF-α, TRAIL.
  • Death receptors: Fas (CD95), TNF receptor 1 (TNFR1), TRAIL receptors DR4/DR5 — members of the TNF receptor superfamily with intracellular death domains (DD).
  • Death domain (DD): Protein–protein interaction module (homotypic DD–DD binding).
  • FADD: Adaptor with a death domain and a death effector domain (DED).
  • Procaspase-8: Initiator caspase with tandem DEDs.
  • DISC: The receptor–FADD–caspase-8 signaling complex.
  • c-FLIP: Caspase-8-like inhibitor that competes for DISC binding.
  • Bid: BH3-only protein whose cleavage (to tBid) links extrinsic to intrinsic pathway.

Mechanism / How It Works

  1. Ligand binding and clustering: FasL (a trimer) binds and clusters three Fas receptors, bringing their intracellular death domains together.
  2. FADD recruitment: The clustered death domains recruit the adaptor FADD via homotypic DD–DD interaction; FADD exposes its death effector domain.
  3. Procaspase-8 recruitment: Procaspase-8 binds FADD via DED–DED interactions, assembling the DISC.
  4. Caspase-8 activation: High local concentration of procaspase-8 promotes dimerization, which activates caspase-8 by induced proximity — two procaspase-8 monomers cleave and stabilize each other into the active heterotetramer.
  5. Execution (Type I): In "Type I" cells (e.g., lymphocytes), active caspase-8 directly cleaves and activates executioner caspases-3/7, which dismantle the cell.
  6. Amplification (Type II): In "Type II" cells (e.g., hepatocytes), the direct signal is weak; caspase-8 cleaves Bid to tBid, which translocates to mitochondria and activates Bax/Bak → MOMP → cytochrome c → apoptosome → caspase-9, amplifying the cascade through the intrinsic pathway.
  7. Regulation: c-FLIP resembles caspase-8 but lacks protease activity and competes for DISC binding, damping the signal.

Energy and Directionality

Like all apoptosis, the extrinsic pathway is ATP-dependent and irreversible once caspases are engaged — proteolysis is a one-way covalent event. The pathway is directional in space too: an extracellular ligand triggers an intracellular protein–protein assembly cascade (DD → DED → caspase cascade), with signal amplification at each layer. The Type I/Type II branch illustrates a design principle: the same receptor signal is either sufficient on its own or routed through the mitochondria for amplification, depending on the cell's threshold.

Experimental Evidence / Technique

  • Fas/FasL immunology: Mutations in Fas (lpr mice) or FasL (gld mice) cause lymphoproliferation and autoimmunity, showing the pathway's role in deleting self-reactive lymphocytes.
  • DISC biochemistry: Immunoprecipitation of the receptor after ligand stimulation recovers FADD and caspase-8, defining the DISC components (Kischkel et al., 1995).
  • Induced-proximity experiments: Artificial dimerization of procaspase-8 (e.g., with chemical dimerizers) activates it, proving dimerization is sufficient.
  • Type I/Type II classification: Cells classified by whether Bcl-2 overexpression blocks Fas-induced death (it blocks Type II but not Type I), revealing the mitochondrial amplification step (Scaffidi et al., 1998).
  • TRAIL and death-receptor agonists: Recombinant TRAIL and agonistic anti-DR4/DR5 antibodies selectively kill many tumor cells, the basis of ongoing cancer trials.

How it works

  1. Ligand binding and clustering: FasL (a trimer) binds and clusters three Fas receptors, bringing their intracellular death domains together.
  2. FADD recruitment: The clustered death domains recruit the adaptor FADD via homotypic DD–DD interaction; FADD exposes its death effector domain.
  3. Procaspase-8 recruitment: Procaspase-8 binds FADD via DED–DED interactions, assembling the DISC.
  4. Caspase-8 activation: High local concentration of procaspase-8 promotes dimerization, which activates caspase-8 by induced proximity — two procaspase-8 monomers cleave and stabilize each other into the active heterotetramer.
  5. Execution (Type I): In "Type I" cells (e.g., lymphocytes), active caspase-8 directly cleaves and activates executioner caspases-3/7, which dismantle the cell.
  6. Amplification (Type II): In "Type II" cells (e.g., hepatocytes), the direct signal is weak; caspase-8 cleaves Bid to tBid, which translocates to mitochondria and activates Bax/Bak → MOMP → cytochrome c → apoptosome → caspase-9, amplifying the cascade through the intrinsic pathway.
  7. Regulation: c-FLIP resembles caspase-8 but lacks protease activity and competes for DISC binding, damping the signal.

Common confusions

  • Extrinsic vs. intrinsic: Extrinsic starts at a cell-surface death receptor (caspase-8); intrinsic starts at the mitochondrion (cytochrome c, caspase-9). Both finish with executioner caspases.
  • caspase-8 vs. caspase-9: Both are initiator caspases, but caspase-8 belongs to the extrinsic (DISC) route and caspase-9 to the intrinsic (apoptosome) route.
  • TNFR1 is not purely apoptotic: It usually signals inflammation and survival (NF-κB); death-receptor apoptosis is cleaner with Fas and TRAIL receptors.
  • Type I vs. Type II: Not different ligands or receptors, but different cell types that differ in whether the mitochondrial amplification step is required.

Quick review

  • FasL/TRAIL → receptor trimerization → DD recruits FADD → DED recruits procaspase-8 → DISC.
  • Caspase-8 dimerizes/activates → caspase-3/7 (Type I) or Bid → tBid → MOMP → caspase-9 (Type II).
  • Regulation: c-FLIP; disease: ALPS (Fas/FasL mutations), cancer (TRAIL agonists as therapy).
Eli, the EliExplains learning guide

Eli explains

The same idea, in plain words

Explain it like I’m 10

Imagine a "self-destruct button" on the outside of a cell — a receptor shaped to fit a specific key (the death ligand). When an immune cell brings the key, three buttons get pressed together, and on the inside they snap together with an adaptor and a pair of scissors (caspase-8). Crowding the scissors together is what turns them on. In some cells the scissors are sharp enough to finish the job alone; in others they are dull, so they cut a "relay" protein (Bid) that runs to the mitochondria and triggers the backup demolition crew. The analogy's limit: "crowding turns on the scissors" is a specific molecular phenomenon (dimerization-induced activation), and the "backup crew" is the entire intrinsic/mitochondrial pathway.

Key takeaways

  • ### High-Yield Facts
  • Ligands: FasL, TNF-α, TRAIL; receptors: Fas, TNFR1, DR4/DR5 (TNF receptor superfamily, with death domains).
  • DISC = receptor + FADD + procaspase-8; assembled via DD–DD and DED–DED interactions.
  • Caspase-8 is activated by induced proximity (dimerization).
  • Type I cells: caspase-8 → caspase-3 directly. Type II cells: caspase-8 → Bid → tBid → MOMP → caspase-9 amplification.
  • c-FLIP inhibits by competing for DISC binding.

Keep learning

Ready to build on this? Continue to the next lesson.

Study tools & related lessonsYou’ll learn to · Related

You’ll learn to

  • Identify the major death receptors and their ligands.
  • Describe how ligand binding assembles the death-inducing signaling complex (DISC).
  • Explain how caspase-8 is activated by induced proximity.
  • Distinguish Type I (direct caspase cascade) from Type II (mitochondrial amplification) cells.
  • Connect Fas/FasL and TRAIL signaling to immune function and cancer therapy.

Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.